Annexon, Inc.

NASDAQ: ANNX · Healthcare · Biotechnology

PublicHQ Brisbane, CA · San MateoCIK 0001528115Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 44DQ —GM —SS 57

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$206.7M

Employees

106

Market cap

$653.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$206.7M-$206.7M2025

Operating income-$216.4M-$216.4M2025

Total assets$277.6M$277.6M2025

Liabilities$65.9M$65.9M2025

Equity$211.6M$211.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Annexon, Inc. earned -$206.7M in FY2025 net income.

Peers · Healthcare

Monopar Therapeutics Inc.59C BridgeBio Oncology Therapeutics Inc.——Esperion Therapeutics, Inc.60C Achieve Life Sciences, Inc.37D

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B87A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B73B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEODouglas E. Love

SectorHealthcare

IndustryBiotechnology

HeadquartersBrisbane, CA

ExchangeNASDAQ: ANNX

Employees106

IPO date2020-07-24

Latest filings

8-K2026-06-12 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-27 10-K2026-03-30 8-K2026-03-30 8-K2026-02-17 8-K2026-01-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.